NCT01241695已完成不适用
Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- postprandial blood glucose (iAUC) (0-240 min)
研究概览
简要总结
The purpose of the study is to determine the safety, acceptability and the efficacy of a 12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic control in type 2 diabetic patients with or at risk of malnutrition
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of type 2 diabetes according to the WHO diagnostic criteria for more than 6 months: Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT (oral glucose tolerance test);
- •HbA1c between 6.5-8.5 % (confirmed in the previous 3 months),
- •capable of using oral nutritional supplementation,
- •on stable and controlled anti-diabetic regime for at least 1 months,
- •use of metformin and/or sulphonylureas as oral anti-diabetic medication,
- •in need of nutritional support because of ≥5% involuntary weight loss in the last 3 months, ≥10% involuntary weight loss in the last 6 months, inadequate nutritional intake causing failure to meet nutritional requirements or at risk of developing malnutrition
排除标准
- •diabetes type 1,
- •participation in a clinical trial with an investigational product or regular use of disease-specific oral nutritional supplements within 4 weeks prior to study start
- •patients requiring a fibre free diet,
- •enteral tube feed or parenteral nutrition,
- •concomitant therapy with systemic glucocorticoids, insulins or anti-diabetic medication other than metformin and sulphonylureas,
- •known or suspected intolerance or allergy to any component of the investigational product(s),
- •any acute gastrointestinal disease within 2 weeks prior to study entry,
- •gastrectomy, gastroparesis or other gastric emptying abnormalities,
- •acute sever heart failure (NYHA class 4), liver insufficiency / failure (male: ALAT > 150 U/l; female: ALAT > 120 U/l) or renal failure requiring dialysis,
- •cancer cachexia,
- •galactosaemia, fructosaemia,
- •suspicion of drug abuse, abuse of/addiction to alcohol,
- •pregnant or breast feeding women, or fertile women refusing to use contraceptives,
- •patients with untreated major psychiatric disorder,
- •known HIV positive (safety reasons),
- •patient unable to co-operate adequately
结局指标
主要结局
postprandial blood glucose (iAUC) (0-240 min)
时间窗: day 84
次要结局
- gastrointestinal tolerance(week 1, week 6, week 12)
- postprandial peak blood glucose (0-240 min)(day 1, day 42, day 84)
- postprandial triglycerides (0-240 min)(day 1, day 42, day 84)
- total cholesterol, HDL-cholesterol, LDL-cholesterol(day 1, day 42, day 84)
- total protein, albumin, prealbumin(day 1, day 42, day 84)
- HbA1c, HOMA-IR index(day 1, day 42, day 84)
- c-peptide(day 1, day 84)
- palatability / taste test(week 1, week 6, week 12)
- daily compliance(day 1-84)
研究者
研究点 (2)
Loading locations...
相似试验
终止
3 期
Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain InjuryTraumatic Brain InjuryNCT00983437Cephalon, Inc.49
已完成
3 期
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With AsthmaAsthmaNCT01244984GlaxoSmithKline243
已完成
不适用
Endurant Stent Graft System Post Approval Study (ENGAGE PAS)Aortic Aneurysm, AbdominalNCT01379222Medtronic Cardiovascular178
已完成
3 期
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01316887GlaxoSmithKline563
Unknown
不适用
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than RisperidoneSchizophrenia, CatatonicSchizophrenia, DisorganizedSchizophrenia, ParanoidPsychotic DisordersSchizophreniaNCT00563017Hospital Authority, Hong Kong30